Chronic Kidney Disease Market

The  increasing prevalence of kidney diseases to boost the market growth

The worldwide rise in the prevalence and incidence of obesity is the main factor driving the growth of the chronic kidney disease device market. For instance, the World Health Organization estimated that over 1 billion people worldwide 650 million adults, 340 million adolescents, and 39 million children are obese as of March 2022. Additionally, by 2025, 167 million people and children who are overweight or obese will also have worse health overall. As a result of the rising obesity rate, more people are anticipated to seek out chronic kidney disease during the forecast period.

The increasing prevalence of kidney diseases, the increasing number of biopsy procedures, and the rising demand for new techniques for diagnosis of chronic diseases are driving the market growth.

September 2023: AWAK Technologies (AWAK), an innovative medical technology company that treats end-stage renal disease via dialysis utilizing regeneration technology, announced, that it has raised more than $20 million in Series B funding. This accomplishment not only represents the most substantial fundraising endeavor undertaken by MedTech to date, but also ranks among the most substantial in Southeast Asia as of this moment.

The round was co-led by venture capital firms Lion X Ventures and Vickers Venture Partners, Advanced MedTech, Eckuity Capital, a United States-based healthcare venture capital fund, and an investment office specializing in the management of multibillion-dollar assets within the healthcare industry. AWAK PD, an ultraportable and wearable peritoneal dialysis (PD) system, offers patients the convenience of conducting dialysis at their residences or while on the move. This solution effectively tackles a prevalent challenge encountered by patients requiring dialysis at present: extended periods of stationary therapy and reliance on cumbersome connections to dialysis machines located in hospitals and clinics.

April 2023: Medtronic, a manufacturer of medical devices, and DaVita formed Mozarc Medical, a corporation committed to the development of renal care technologies, focusing specifically on at-home remedies. The fact that Medtronic and DaVita each own an equal equity stake in the company was made public nearly a year ago. It was confirmed by executives from both DaVita and Medtronic that the two organizations provided an initial funding of $200 million in cash for the establishment of the company. The corporations shall contribute future operating capital to ensure the organization's continued operations.

Mozarc will be governed by a six-member board of directors, of which two will be appointed from each company and two will be independent directors. According to the companies, Mozarc Medical will expand the capacity of dialysis delivery systems and other technologies utilized in the treatment of advanced phases of kidney disease by leveraging DaVita's expertise in dialysis services and Medtronic's proficiency in medical devices.

Kidney illness, and the rising number of biopsy operations are all factors fueling the market. Increases in governmental spending and the development of more sensitive diagnostic tools for identifying CKD at an early stage are further factors that should drive the market forward.

The chronic kidney disease (CKD) market is expected to increase because of factors such as the increasing popularity of transplantation therapy and the presence of a sizable elderly population. The high level of R&D activity in the expansion of CKD medications and the favorable reimbursement policies in emerging nations are also expected to drive the market growth rate. Market growth for chronic kidney disease (CKD) is also predicted to be influenced by the focus of various manufacturers on innovation and technological breakthroughs in treatment.

The prevalence of CKD is high and rising in many regions of the world, which is expected to boost demand for blood testing. End-stage renal disease (ESRD) is extremely common and rapidly increasing in prevalence around the world. As a result, it opens up new avenues for business expansion.In July, 2023, Recent work by a team at the University of Edinburgh sheds light on a protein associated to kidney and heart damage, which may lead to new approaches to treating chronic kidney disease.

Researchers have found that the protein Indian Hedgehog (IHH) promotes scarring in the kidneys and hearts of mice. Damaged or aging kidneys manufacture and release this protein from certain cells. Chronic kidney disease (CKD) affects 10% of the global population, and experts say further research is needed to investigate IHH as a possible target for medicines to treat CKD.

The Global Chronic Kidney Disease Market Industry is poised for substantial growth, with projections indicating a market value of 40.5 USD Billion in 2024 and a remarkable increase to 75.2 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 5.78% from 2025 to 2035. The factors contributing to this growth include rising CKD prevalence, advancements in treatment and diagnostic technologies, and increased healthcare expenditure. As the market evolves, it is likely to attract investments and innovations aimed at improving patient care and outcomes, thereby solidifying its position in the global healthcare landscape.

The rise in global healthcare expenditure is a significant factor driving the Global Chronic Kidney Disease Market Industry. Governments and private sectors are investing more in healthcare infrastructure, particularly in chronic disease management. This increased funding facilitates the development of new therapies, improved healthcare facilities, and better access to treatment for CKD patients. As healthcare spending continues to rise, it is likely to enhance the availability and affordability of CKD management options. This trend is expected to support the market's growth, aligning with the anticipated increase in market value to 75.2 USD Billion by 2035.

Technological advancements in diagnostic tools are transforming the landscape of the Global Chronic Kidney Disease Market Industry. Innovations such as point-of-care testing, imaging techniques, and biomarker discovery are enabling earlier detection and more accurate monitoring of CKD. For instance, the introduction of non-invasive tests allows for timely interventions, which can significantly improve patient outcomes. As healthcare providers increasingly adopt these technologies, the demand for advanced diagnostic solutions is anticipated to rise. This trend not only enhances patient care but also contributes to the overall growth of the market, which is projected to reach 40.5 USD Billion in 2024.

The emergence of innovative treatment options for chronic kidney disease is reshaping the Global Chronic Kidney Disease Market Industry. Recent advancements in pharmacotherapy, including novel medications and biologics, are providing new avenues for managing CKD. These innovations not only improve patient outcomes but also expand the treatment landscape, catering to diverse patient needs. As healthcare providers adopt these new therapies, the demand for effective CKD treatments is likely to surge. This trend aligns with the overall market growth, which is projected to reach 40.5 USD Billion in 2024, reflecting the increasing focus on personalized medicine and targeted therapies.

There is a notable increase in awareness and education initiatives regarding chronic kidney disease, which is positively influencing the Global Chronic Kidney Disease Market Industry. Various health organizations and governments are actively promoting CKD awareness campaigns aimed at educating the public about risk factors, prevention, and management strategies. These initiatives are crucial in encouraging early diagnosis and treatment, ultimately leading to better health outcomes. As awareness grows, more individuals are likely to seek medical attention, thereby driving demand for CKD-related healthcare services and products. This trend is expected to contribute to the market's expansion as it aligns with the projected growth trajectory.

The increasing prevalence of chronic kidney disease (CKD) globally serves as a primary driver for the Global Chronic Kidney Disease Market Industry. As of 2024, approximately 850 million individuals worldwide are affected by CKD, with the numbers projected to rise significantly. This surge is attributed to factors such as aging populations, rising rates of diabetes and hypertension, and lifestyle changes. The growing patient base necessitates enhanced healthcare services and innovative treatment options, thereby propelling market growth. By 2035, the market is expected to reach 75.2 USD Billion, reflecting a compound annual growth rate (CAGR) of 5.78% from 2025 to 2035.

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America chronic kidney disease market is expected to be the fastest growing during the study period. This is attributed to the rising prevalence of chronic kidney diseases, the presence of well-established healthcare infrastructure along with high health spending, and technologically advanced diagnostic tests in the region. Moreover, the primary reason fueling the market's expansion is the rising prevalence of chronic kidney diseases in the population.

For instance, according to a study released in February 2022 by the American Kidney Fund, 92,000 Americans are waiting for kidney transplants and an estimated 37 million Americans have kidney disease. Therefore, the rising rates of chronic renal disease, a developed healthcare system, high health spending, and technologically sophisticated diagnostic procedures are the main drivers of market expansion.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: Chronic Kidney Disease Market Share By Region, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

Europe chronic kidney disease market is expected to account for the second-largest market share due to the increasing incidences of chronic kidney diseases and growth in government expenditure in the healthcare sector in the region. Further, the Germany chronic kidney disease market is expected to hold 3rd place for the market share, and the UK chronic kidney disease market is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France chronic kidney disease market will hold the 5th place for the market share.

The Asia-Pacific chronic kidney disease market is expected to grow at a high CAGR from 2024 to 2032. This is due to the due to the increasing incidences of end-stage diseases and high development in government expenditure in the healthcare industry in the Asia-Pacific region. Moreover, India chronic kidney disease market is expected to hold the largest market share, and China chronic kidney disease market is expected fastest-growing market in the Asia-Pacific region.

Furthermore, India is considered as one of the countries with the highest growth rates in the healthcare sector. Due to an increase in life expectancy and illnesses brought on by a sedentary lifestyle is considerably increasing which will fuel the growth for the chronic kidney disease market.

The Rest of the World includes the Middle East, Africa, and Latin America. This segment is projected to hold the least share in the chronic kidney disease market. In this region, the Middle East is anticipated to dominate owing to the as rising prevalence of diabetes resulting in renal diseases and rising incidences of renal diseases in the region. Furthermore, growing funding and participation from the public and private sectors in R&D initiatives, as well as advancements in the infrastructure of the area, encourage market growth.

The chronic kidney disease market is characterized by the presence of many global, regional, and local vendors catering to the demand created by research scientists and pharmaceutical and biotechnology companies operating in the industry. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Abbott (US), Siemens (Germany), Beckman Coulter (US), and F. Hoffmann-La Roche Ltd (Switzerland) the chronic kidney disease market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development.

Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.

One of the primary business strategies adopted by manufacturers in the chronic kidney disease industry to benefit clients and expand the chronic kidney disease market sector is to manufacture locally to reduce operating costs.

GlaxoSmithKline Plc (UK) is a science-led healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines, and consumer healthcare. It is one of the few healthcare companies researching both medicines and vaccines for the world health organization’s three prime diseases, HIV/Aids, tuberculosis, meningococcal, and malaria. The company has also developed some of the leading medicines in these fields. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers.

It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. For instance, in June 2020, GlaxoSmithKline Plc (UK) received regulatory approval for Duvroq (daprodustat) in Japan for patients with anemia due to chronic kidney disease.

Also, F. Hoffmann-La Roche Ltd (Roche) develops & markets products for diagnosis & treatment of anemia, cancer, anticoagulation therapy, cardiovascular diseases, diabetes, central nervous system, chlamydia, dermatology, gonorrhea, gout, hepatitis B and C, hemostasis disorders, HIV/AIDS, HPV, infectious diseases, and autoimmune diseases. The company specializes in the field of molecular diagnostics & medicines for oncology, virology, inflammation, metabolism, central nervous system (CNS), clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. The firm operates in two major business segments, namely, pharmaceuticals and diagnostics. The company has strong presence in North America, Europe, Asia, and the Middle East.